T1? MRI OF PATIENTS WITH ALZHEIMER?S DISEASE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 阿尔茨海默病（AD）是一种神经退行性疾病，是痴呆症的最常见形式 在老年人中发现。 目前，没有现有的治疗AD的方法，部分原因是缺乏早期治疗。 疾病的诊断。 AD影响大脑的早期变化被认为发生在 随着神经纤维缠结（NFT）和老年斑（SP）的生长， 导致大分子退化和细胞死亡。 最新MRI技术 只能测量在疾病进展后期发生的大体形态学变化， 然而，存在称为T1 p的替代MRI造影剂。 早期大分子变化 将改变本体水的T1 p弛豫时间，从而提供对AD进展的早期体内观察。 在该项目中，测量AD、轻度认知障碍（MCI）和 对照人群评估T1 p诊断AD的能力。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Alzheimer's Disease (AD) is a neurodegenerative disease that is the most common form of dementia found in the elderly. Currently, there is no existing treatment for AD in part due to lack of early diagnosis of the disease. Early changes in AD affected brains are thought to occur on a biochemical scale with the growth of neurofibrilary tangles (NFTs) and senile plaques (SPs) which lead to macromolecular deterioration and cell death. Current state of the art MRI techniques can only measure gross morphological changes that occur late in the disease progression, however an alternate MRI contrast exists which is called T1p. Early macromolecular changes will alter the bulk water T1p relaxation times providing an earlier in vivo look at AD progression. In this project, T1p relaxation times are measured in AD, mildly cognitively impaired (MCI) and control populations to assess the ability of T1p to diagnose AD.